BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
24 results:

  • 1. The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications.
    Park HS; Kim HK; Kim HS; Yang Y; Han HS; Lee KH; Son BR; Kwon J
    Ann Hematol; 2022 Dec; 101(12):2645-2654. PubMed ID: 36220882
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
    Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
    Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
    Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
    Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
    Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
    Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
    Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia.
    Wu L; Xia M; Sun X; Han X; Zu Y; Jabbour EJ; You MJ; Lin P; Li S; Xu J; Han H; Bueso-Ramos CE; Medeiros LJ; Qiu X; Yin CC
    Eur J Haematol; 2020 Oct; 105(4):449-459. PubMed ID: 32535947
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
    Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
    Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
    Roberts KG; Reshmi SC; Harvey RC; Chen IM; Patel K; Stonerock E; Jenkins H; Dai Y; Valentine M; Gu Z; Zhao Y; Zhang J; Payne-Turner D; Devidas M; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Mattano LA; Maloney KW; Carroll WL; Loh ML; Willman CL; Gastier-Foster JM; Mullighan CG; Hunger SP
    Blood; 2018 Aug; 132(8):815-824. PubMed ID: 29997224
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
    Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
    Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic leukemia: A Genome Sequencing Study.
    Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
    PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.
    de Smith AJ; Ojha J; Francis SS; Sanders E; Endicott AA; Hansen HM; Smirnov I; Termuhlen AM; Walsh KM; Metayer C; Wiemels JL
    Oncotarget; 2016 Nov; 7(45):72733-72745. PubMed ID: 27683039
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
    Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
    Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Activated kras Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate leukemia.
    Prieto C; Stam RW; Agraz-Doblas A; Ballerini P; Camos M; Castaño J; Marschalek R; Bursen A; Varela I; Bueno C; Menendez P
    Cancer Res; 2016 Apr; 76(8):2478-89. PubMed ID: 26837759
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
    Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
    Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
    Sakaguchi H; Okuno Y; Muramatsu H; Yoshida K; Shiraishi Y; Takahashi M; Kon A; Sanada M; Chiba K; Tanaka H; Makishima H; Wang X; Xu Y; Doisaki S; Hama A; Nakanishi K; Takahashi Y; Yoshida N; Maciejewski JP; Miyano S; Ogawa S; Kojima S
    Nat Genet; 2013 Aug; 45(8):937-41. PubMed ID: 23832011
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
    Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
    Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia.
    Yang X; Qian J; Sun A; Lin J; Xiao G; Yin J; Chen S; Wu D
    Clin Biochem; 2013 May; 46(7-8):579-83. PubMed ID: 23313659
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
    Shimada A; Taki T; Koga D; Tabuchi K; Tawa A; Hanada R; Tsuchida M; Horibe K; Tsukimoto I; Adachi S; Kojima S; Hayashi Y
    Int J Hematol; 2012 Oct; 96(4):469-76. PubMed ID: 22915059
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.
    Balgobind BV; Hollink IH; Arentsen-Peters ST; Zimmermann M; Harbott J; Beverloo HB; von Bergh AR; Cloos J; Kaspers GJ; de Haas V; Zemanova Z; Stary J; Cayuela JM; Baruchel A; Creutzig U; Reinhardt D; Pieters R; Zwaan CM; van den Heuvel-Eibrink MM
    Haematologica; 2011 Oct; 96(10):1478-87. PubMed ID: 21791472
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. kras mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
    Ogino S; Meyerhardt JA; Irahara N; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Goldberg RM; Bertagnolli MM; Fuchs CS; ; ; ;
    Clin Cancer Res; 2009 Dec; 15(23):7322-9. PubMed ID: 19934290
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.